The use of reverse transcription-PCR for the diagnosis of X-linked chronic granulomatous disease

Brazilian Journal of Medical and Biological Research

Volumn 37, Issue 5, 2004, Pages 625-634

  Agudelo Florez P ^a   Lopez J A ^a   Redher, J ^a   Carneiro Sampaio, M M S ^b   Costa Carvalho, B T ^c   Grumach, A S ^b   Condino Neto, A ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Human; Neutrophils; Phagocytes; Primary immunodeficiency; Respiratory burst; Superoxide

Indexed keywords

COMPLEMENTARY DNA; NITROBLUE TETRAZOLIUM; PRIMER DNA; RNA; SUPEROXIDE;

ARTICLE; B LYMPHOCYTE; BRAZIL; CHILD; CHRONIC GRANULOMATOUS DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; EXON; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; HUMAN; INTRON; MALE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; RESPIRATORY BURST; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCREENING TEST; X CHROMOSOME LINKED DISORDER;

HUMAN HERPESVIRUS 4;

EID: 2542597116     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2004000500001     Document Type: Article

References (39)

1. Berendes H, Bridges RA & Good RA (1957). A fatal granulomatosus of childhood: the clinical study of a new syndrome. Minnesota Medicine, 40: 309-312.
2. Landing BH & Shirkey HS (1957). A syndrome of recurrent infection and infiltration of the viscera by pigmented lipid histiocytes. Pediatrics, 20: 431-442.
3. Patterson EL, Milstrey R & Stokstad ELR (1975). Effect of selenium in preventing exudative diathesis in chicks. Proceedings of the Society for Experimental Biology and Medicine, 95: 617-620.
4. Tauber AI, Borregaard N, Simons ER & Wright J (1983). Chronic granulomatous disease A syndrome of phagocyte oxidase deficiencies. Medicine, 62: 286-309.
5. Forrest CB, Forehand JR, Axtell RA, Roberts RL & Johnston Jr RB (1988). Clinical features and current management of chronic granulomatous disease. Hematology/Oncology Clinics of North America, 2: 253-266.
6. Curnutte JT (1993). Chronic granulomatous disease: the solving of a clinical riddle at the molecular level. Clinical Immunology and Immunopathology, 67: S2-S15.
7. Dinauer MC, Orkin SH, Brown R, Jesaitis AJ & Parkos CA (1987). The glycoprotein encoded by the X-linked chronic granulomatous disease locus is a component of the neutrophil cytochrome b complex. Nature, 327: 717-720.
8. Heyworth PG, Curnutte JT, Rae J, Noack D, Roos D, van Koppen E & Cross AR (2001). Hematologically important mutations: X-linked chronic granulomatous disease (second update). Blood Cells, Molecules and Diseases, 27: 16-26.
9. Clark RA, Malech HL, Gallin JI, Nunoi H, Volpp BD, Pearson DW, Nauseef WM & Curnutte JT (1989). Genetic variants of chronic granulomatous disease: Prevalence of deficiencies of two cytosolic components of the NADPH oxidase system. New England Journal of Medicine, 321: 647-652.
10. Cross AR, Noack D, Rae J, Curnutte JT & Heyworth PG (2000). Hematologically important mutations: the autosomal recessive forms of chronic granulomatous disease (first update). Blood Cells, Molecules and Diseases, 26: 561-565.
11. Smith RM & Curnutte JT (1991). Molecular basis of chronic granulomatous disease. Blood, 77: 673-686.
12. Vowells SJ, Fleisher TA, Sekhsaria S, Alling DW, Maguire TE & Malech HL (1996). Genotype-dependent variability in flow cytometric evaluation of reduced nicotinamide adenine dinucleotice phosphate oxidase function in patients with chronic granulomatous disease. Journal of Pediatrics, 128: 104-107.
13. Roos D, de Boer M, Kuribayashi F et al. (1996). Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease. Blood, 87: 1663-1681.
14. Conley ME, Notarangelo LD & Etzioni A (1999). Diagnostic criteria for primary immunodeficiencies. Clinical Immunology, 93: 190-197.
15. Condino-Neto A & Newburger PE (1998). NADPH oxidase activity and cytochrome b558 content of human Epstein-Barr virus transformed B lymphocytes correlate with expression of genes encoding components of the oxidase system. Archives of Biochemistry and Biophysics, 360: 158-164.
16. Condino-Neto A & Newburger PE (2000). Interferon-gamma improves splicing efficiency of CYBB gene transcripts in an interferon-responsive variant of X-linked chronic granulomatous disease due to a splice site consensus region mutation. Blood, 95: 3548-3554.
17. Aoshima M, Nunoi H, Shimazu M, Shimizu S, Tatsuzawa O, Kenney RT & Kanegasaki S (1996). Two-exon skipping due to a point mutation in p67-phox-deficient chronic granulomatous disease. Blood, 88: 1841-1845.
18. Azuma H (1994). DNA analysis of cytochrome b positive chronic granulomatous disease (a case report). Rinsho Byori, 42: 242-248.
19. Bonizzato A, Russo MP, Donini M & Dusi S (1997). Identification of a double mutation (D160V-K161E) in the p67phox gene of a chronic granulomatous disease patient. Biochemical and Biophysical Research Communications, 231: 861-863.
20. Borgato L, Bonizzato A, Lunardi C, Dusi S, Andrioli G, Scarperi A & Corrocher R (2001). A 1.1-kb duplication in the p67-phox gene causes chronic granulomatous disease. Human Genetics, 108: 504-510.
21. Noack D, Heyworth PG, Newburger PE & Cross AR (2001). An unusual intronic mutation in the CYBB gene giving rise to chronic granulomatous disease. Biochimica et Biophysica Acta, 1537: 125-131.
22. Roesler J, Curnutte JT, Rae J, Barrett D, Patino P, Chanock SJ & Goerlach A (2000). Recombination events between the p47-phox gene and its highly homologous pseudogenes are the main cause of autosomal recessive chronic granulomatous disease. Blood, 95: 2150-2156.
23. De Boer M, Singh V, Dekker J, Di Rocco M, Goldblatt D & Roos D (2002). Prenatal diagnosis in two families with autosomal, p47(phox)-deficient chronic granulomatous disease due to a novel point mutation in NCF1. Prenatal Diagnosis, 22: 235-240.
24. Baehner RL, Millar-Groff S & Bringas P (1999). Developmental expression of NADPH phagocytic oxidase components in mouse embryos. Pediatric Research, 46: 152-157.
25. Banerjee R, Anguita J, Roos D & Fikrig E (2000). Cutting edge: infection by the agent of human granulocytic ehrlichiosis prevents the respiratory burst by down-regulating gp91 phox. Journal of Immunology, 164: 3946-3949.
26. Bayraktutan U, Blayney L & Shah AM (2000). Molecular characterization and localization of the NAD(P)H oxidase components gp91-phox and p22-phox in endothelial cells. Arteriosclerosis, Thrombosis and Vascular Biology, 20: 1903-1911.
27. Cobbs S, Malech HL, Leto TL, Freeman SM, Blaese RM, Gallin JI & Lomax KJ (1992). Retroviral expression of recombinant p47phox protein by Epstein-Barr virus-transformed B lymphocytes from a patient with autosomal chronic granulomatous disease. Blood, 79: 1829-1835.
28. Gorlach A, Brandes RP, Nguyen K, Amidi M, Dehghani F & Busse R (2000). A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circulation Research, 87: 26-32.
29. Rouzaut A, Lopez-Moratalla N & de Miguel C (2000). Differential gene expression in the activation and maturation of human monocytes. Archives of Biochemistry and Biophysics, 374: 153-160.
30. Patiño PJ, Perez JE, Lopez JA, Condino-Neto A, Grumach AS, Botero JH, Curnutte JT & Garcia de Olarte D (1999). Molecular analysis of chronic granulomatous disease caused by defects in gp91-phox. Human Mutation, 13: 29-37.
31. Ochs HD & Igo RP (1973). The NBT slide test: a simple screening method for detecting chronic granulomatous disease and female carriers. Journal of Pediatrics, 83: 77-82.
32. Boyum A (1968). Isolation of mononuclear cells and granulocytes from human blood. Scandinavian Journal of Clinical and Laboratory Investigation, 21 (Suppl 97): 1-77.
33. Condino-Neto A, Muscara MN, Grumach AS, Carneiro-Sampaio MMS & de Nucci G (1993). Neutrophils and mononuclear cells from patients with chronic granulomatous disease release nitric oxide. British Journal of Clinical Pharmacology, 35: 485-490.
34. McCord J & Fridovich I (1969). Superoxide dismutase: An enzymatic function for erythrocuprein (hemocuprein). Journal of Biological Chemistry, 244: 6044-6055.
35. Condino-Neto A, Muscara MN, Grumach AS, Bellinati-Pires R, Brandao AC, Carneiro-Sampaio MMS & de Nucci G (1996). The effect of recombinant human interferon-gamma therapy on neutrophil and mononuclear cell nitric oxide release from patients with chronic granulomatous disease. Journal of Interferon and Cytokine Research, 16: 357-364.
36. Volkman DJ, Buescher ES, Gallin JI & Fauci AS (1984). B cell lines as models for inherited phagocytic diseases: superoxide generation in chronic granulomatous disease and granules in Chediak-Higashi syndrome. Journal of Immunology, 133: 3006-3009.
37. Nilsson K, Klein G, Henle W & Henle G (1971). The establishment of lymphoblastoid cell lines from adult and fetal human lymphoid tissue and its dependence on EBV. International Journal of Cancer, 8: 443-450.
38. Ginsburg D, Handin RI, Bonthron DT, Donlon TA, Bruns GAP, Latt SA & Orkin SH (1985). Human von Willebrand factor: Isolation of complementary DNA clones and chromosomal location. Science, 228: 1401-1406.
39. Subrahmanyam YVBK, Baskaran N, Newburger PE & Weissman SM (1999). A modified method for the display of 3′-end restriciton fragments of cDNAs: Molecular profiling of gene expression in neutrophils. Methods in Enzymology, 303: 272-297.